Etodolac is classified as a non-steroidal inflammatory drug. NSAIDs such as etodolac are known inhibitors of cyclooxygenase, which are responsible in the formation of biological mediators such as prostanoids, and prostaglandin. Inhibiting cyclooxygenase may relieve a person from pain, and the symptoms of inflammation.
The etodolac drug is produced by Shire pharmaceuticals under the trade name Lodine SR, and also by the Meda Industry under the brand name Eccoxolac.
Etodolac is indicated for the treatment of pain and inflammation caused by ailments such as osteoarthritis and rheumatoid arthritis. It is also used for acute pain management.
Etodolac administration is done via the oral route. The drug is formulated as 200 and 300 mg capsules and 400 and 500mg tablets. As an analgesic, the recommended dose of etodolac is up to 1g (1000mg), taken at 200 to 400 mg every six to eight hours.
For the treatment of osteoarthritis and rheumatoid arthritis, the initial dosage is at 300, 400 and/or 500 mg twice a day. For long term administration, lower doses of 600 mg per day may be enough.
Etodolac use may cause side effects and at times adverse reactions to the drug. Common side effects include diarrhea, bloating, vomiting, constipation, headaches, dizziness, blurred vision, sore throat, runny nose and ringing in the ears.
There may be serious side effects posed by usage of the drug, which should immediately be reported to the doctor. Some side effects include swelling of the face, tongue, lips, extremities (hands, feet, legs), chills, fever, rashes, difficulty in breathing and swallowing, back pain, weight gain/loss, appetite loss, flu-like symptoms, irregular heartbeats, discolored or bloody urine coloration and pain while urinating.
Etodolac is found to be contraindicated in patients with a known hypersensitivity to the drug and its known components. It is also not advised to be administered to patients with asthma, urticaria or other known allergic reactions after taking aspirins and other NSAIDs. Anaphylactic reactions which range from sever to fatal may occur in NSAID reactions.
Etodolac is also contraindicated in the treatment of peri-operative pain in coronary artery bypass graft surgery setting.
Patients with peptic ulcers and impaired kidney functions should also avoid the drug as it may aggravate the condition. Caution is to be exercised when taking etodolac concomitantly with blood thinning drugs, or anticoagulants because of the increase in the risk of bleeding. Etodolac has also been found out to interact with certain anti-depressants such as fluoxetine, which may increase the risk of strokes and heart attacks.
Etodolac is not advised to be taken by persons having more than 3 alcoholic beverages per day, as the risk of developing ulcers is increased. The long-term use of etodolac has been reported to cause papillary necrosis and kidney impairment. Elevated dosages of etodolac, along with prolonged use leads to toxicity of the kidney.
Etodolac is generally not advised to be given to pregnant women, as the drug etodolac may cause a premature closing of the ductus arteriosus. Although etodolac is not known to be excreted in breast milk, nursing mothers are advised not to take etodolac while breastfeeding.
Etodolac has the following structural formula:
• Molecular formula of etodolac is C17H21NO3
• Chemical IUPAC Name is 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid
• Molecular weight is 287.354 g/mol
• Etodolac available : 200mg capsules, 300mg capsules, 400mg capsules and 500mg capsules
Brand name(s): Etodolaco, Etodolacum, Etodolic Acid, Lodine, Lodine XL, Ultradol
Review published on: 06 August 2009
 Your Etodolac review
Other popular drugs: Atenolol ::
Dantrolene ::
Codicompren
|
Home
E-Mail
Site Map
http://www.medical-look.com
FORUM 
Buy Etodolac
